Table 1.

Medicare beneficiary copay spending for anti-VEGF therapy on fixed- or personalized-injection schedules

Drug	ranibizumab	bevacizumab	aflibercept
Number of patients	995,396	2,020,091	446,915
Average number of annual injections on personalized-injection schedule	5.6	6.7	4.7
Drug copay cost	$288	$9	$242
OCT imaging copay cost	$6	$6	$6
Injection copay cost	$20	$20	$20
Fixed-injection schedule – annual patient copay	$3,693	$342	$1,568
Personalized-injection schedule – annual patient copay	$1,776	$247	$1,262
Annual patient savings	$1,918	$94	$306
Total cohort savings	$1,908,804,551	$190,892,790	$136,910,501
Total injections avoided	6,370,534	10,706,482	580,990